Navigation Links
Regado Biosciences, Inc. to Provide Third Quarter 2013 Financial Results
Date:10/31/2013

BASKING RIDGE, N.J., Oct. 31, 2013 /PRNewswire/ -- Regado Biosciences, Inc. (Nasdaq: RGDO), a biopharmaceutical company focused on the late-stage clinical development of its first-in-class, actively controllable antithrombotic drug system, REG1, today announced Regado's senior management will host a third quarter earnings conference call and live audio webcast on Thursday, November 7, 2013, at 8:30 a.m. ET to discuss recent activities and upcoming plans.

Interested participants and investors may access the conference call by dialing (877) 870-4263 (U.S.), (855) 669-9657 (Canada) or (412) 317-0790 (international). An audio webcast will be accessible via the Investor Relations section of the Regado website, www.regadobio.com.  

A telephonic replay of the call will be available for 90 days beginning approximately one hour following the end of the conference call.  Access numbers for this replay are (877) 344-7529 (U.S./Canada) and (412) 317-0088 (international); conference ID: 10036564. The webcast replay will remain available for 90 days in the Investor Relations section of the Regado website.

ABOUT REGADO BIOSCIENCES
Regado Biosciences, Inc. is a biopharmaceutical company focused on the development of novel, first-in-class, actively controllable antithrombotic drug systems for acute and sub-acute cardiovascular indications.  Regado is pioneering the development of two-component drug systems consisting of a therapeutic aptamer and its specific active control agent. The company's lead product candidate, REG1, is a two-component system consisting of pegnivacogin, an anticoagulant aptamer specifically targeting coagulation Factor IXa, and its complementary oligonucleotide active control agent, anivamersen.  REG1 is being developed for use in patients with a wide variety of acute coronary syndromes, or ACS, undergoing a percutaneous coronary intervention, or PCI, a hospital-based procedure used to mechanically open or widen obstructed coronary arteries. Regado's actively controllable product candidates have the potential to improve patient outcomes, enhance the patient experience and reduce overall treatment costs. More information can be found at www.regadobio.com.

For more information on Regado's Phase 3 REGULATE-PCI clinical study, please visit:
http://www.clinicaltrials.gov/ct2/show/NCT01848106?term=Regado&rank=1

Contact:

Tiberend Strategic Advisors, Inc.

Investors - Joshua Drumm, Ph.D.
jdrumm@tiberend.com; (212) 375-2664

Media - Andrew Mielach
amielach@tiberend.com; (212) 375-2694


'/>"/>
SOURCE Regado Biosciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Regado Biosciences, Inc. to Present at the Cowen and Company 32nd Annual Health Care Conference in Boston, MA
2. Regado Biosciences, Inc. to Present at Needham & Companys 11th Annual Healthcare Conference in New York, NY
3. Regado Biosciences, Inc. Files Registration Statement for Proposed Initial Public Offering
4. Regado Biosciences, Inc. Announces Exercise of Over-Allotment Option
5. Regado Biosciences, Inc. to Present at Aegis Capital Vegas Healthcare Conference
6. Shire to Acquire FerroKin BioSciences, Inc., and its Phase 2 Iron Chelator Treatment
7. Pressure BioSciences, Inc. Reaches Agreement with Investors on Initial $600,000 Tranche of $1.2 Million Above-Market Private Placement; Proceeds to Support Continued Commercialization of PCT Product Platform
8. Pressure BioSciences, Inc. Continues Global Sales Reach Expansion with Distribution Agreements for China, Vietnam, Laos, Cambodia, Australia, and New Zealand
9. Pressure BioSciences, Inc. Appoints Conrad F. Mir as Chief Financial Officer
10. Pressure BioSciences, Inc. to Discuss First Quarter 2013 Financial Results and Provide Business Update
11. Pressure BioSciences, Inc. Closes Final Tranche of Series J Above Market Private Placement - Total Amount Raised in PIPE Slightly Exceeds $2 Million Goal
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/19/2017)... New York (PRWEB) , ... May 19, 2017 , ... ... techniques in treating gait disorders, Biodex Medical Systems, Inc. announces the release of their ... music therapy has been joined with a biomedical system to aid in rehabilitating individuals ...
(Date:5/18/2017)... ... May 18, 2017 , ... ... April 28, 2017 at the Prince Of Wales Private Hospital. The procedure was ... level C6-C7. The patient failed conservative treatments prior to undergoing surgery. , The ...
(Date:5/18/2017)... ... May 16, 2017 , ... Clinical Supplies Management (“CSM”), ... as the company continues to grow. CSM has doubled in size over the ... executing an aggressive growth strategy. , Roger Gasper joins CSM as Chief Financial Officer. ...
(Date:5/18/2017)... ... May 17, 2017 , ... ... further enhances its scientific power by providing investigators access to a high-profile ... to join the scientific advisory board. “We are committed to offering superior ...
Breaking Biology Technology:
(Date:3/27/2017)... N.Y. , March 27, 2017  Catholic ... Information and Management Systems Society (HIMSS) Analytics for ... EMR Adoption Model sm . In addition, CHS ... of U.S. hospitals using an electronic medical record ... for its high level of EMR usage in ...
(Date:3/23/2017)... Research and Markets has announced the addition ... - Industry Forecast to 2025" report to their offering. ... The Global Vehicle ... around 8.8% over the next decade to reach approximately $14.21 billion ... estimates and forecasts for all the given segments on global as ...
(Date:3/20/2017)... HANOVER, Germany , March 20, 2017 At ... Hamburg -based biometrics manufacturer DERMALOG. The Chancellor came to the ... Japan is this year,s CeBIT partner country. At the largest ... important biometrics in use: fingerprint, face and iris recognition as well as ... ...
Breaking Biology News(10 mins):